CD47 Inhibitor Market : Competitive Landscape, Pipeline, and Market Analysis 2023

CD47 (Cluster of Differentiation 47) also known as integrin-associated protein (IAP) is a transmembrane protein that in humans is encoded by the CD47 gene. CD47 belongs to the immunoglobulin superfamily and partners with membrane integrins and also binds the ligands thrombospondin-1 (TSP-1) and signal-regulatory protein alpha (SIRPα). CD47 is involved in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. Furthermore, it plays a key role in immune and angiogenic responses. CD47 is ubiquitously expressed in human cells and has been found to be overexpressed in many different tumor cells. CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers and more recently for the treatment of pulmonary fibrosis. The mechanism of action (MOA) of CD47 Inhibitor is CD47 ligation induces apoptosis of tumor cells through a caspase-independent mechanism. Secondly, anti-CD47 leads to tumor cell phagocytic uptake by antigen-presenting cells and subsequent antigen presentation to T cells. CD47 inhibitors are used in the treatment of lymphoma, acute myelogenous leukemia, adenocarcinoma, carcinoid tumor, cholangiocarcinoma, etc. Increased prevalence of adenocarcinoma and leukemia and increase investment in R&D are the key drivers for the CD47 Inhibitor market. For instance, according to the World Health Organization 2020, there were an estimated 4.3 million cases reported of all types of cancers. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in CD47 Inhibitors and to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instance, Gilead’s Magrolimab (GS-4721) for the indication of patients with acute myeloid leukemia is under the various stages of clinical studies.

CD47 Inhibitor Market Key Developments:

In May 2018, Forty Seven Inc’s 5F9 was the first-in-class CD47 monoclonal antibody approved by the Food and Drug Administration (FDA) for the treatment of two types of lymphomas Relapsed-Refractory B-cell non-Hodgkin lymphomas.

Drugs under the Pipeline for CD47 Inhibitor:

• Magrolimab (GS-4721)
• RRX-001
• Evorpacept (ALX148)
• Ligufalimab (AK117)
• Maplirpacept (PF-07901801)
• Simridarlimab (IBI-322)
• Lemzoparlimab (ABBV-IMAB-TJC4)
• Letaplimab (IBI188)
• 6MW3211
• HX-009
• SL-172154
• IMM01
• IMM0306
• Ontorpacept (TTI-621)
• AO-176
• BAT7104
• CC-90002
• DSP-107
• IMC002
• IMM2902
• NI-1701
• TQB2928
• VT1021
• Gentulizumab
• AUR103
• CC-96673
• HCB101
• HMPL-A83
• IMM2520
• ISB 1442
• JMT601
• LB101
• MIL95
• NI-1801
• PF-07257876
• PT217
• PT886
• SG1906
• SG2501
• SGN-CD47M
• SHR-1603
• STI-6643
• Ti-061
• ZL-1201
• Ontorpacept Intratumoral (TTI 621 Intratumoral)
• Urabrelimab (SRF231)

Clinical Activity and Developments of CD47 Inhibitor:

• Up until June 2023, there will be about 33 companies with over 35 compounds that focus on various forms of cancer diseases. For these molecules, more than 75 of clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,
• In July 2021, Akeso Biopharma has completed a phase 1 multicenter, open label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, and antitumor activity of Ligufalimab (AK117) as monotherapy or in combination with AK104 in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas.
• In June 2023, EpicentRx’s RRX-001 has received FDA’s fast track designation grant based on phase 2a randomized, parallel group, open label, multicenter study to assess the safety and efficacy of RRX-001 in patients receiving chemoradiation for the treatment of locally advanced squamous cell carcinoma of the oral cavity.